Drug Profile
Amlodipine/valsartan/hydrochlorothiazide - Novartis
Alternative Names: Copalia HCT; Dafiro HCT; Exforge HCT; Imprida HCTLatest Information Update: 19 Sep 2018
Price :
$50
*
At a glance
- Originator Novartis
- Class Antihypertensives; Benzothiadiazines; Branched-chain amino acids; Dihydropyridines
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 25 Aug 2018 Adverse events data from a phase III trial in Hypertension presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2018)
- 03 Dec 2014 Launched prior to this date for Hypertension in Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Netherlands, Poland, Spain, Switzerland, Australia, Norway, Turkey, Malaysia, Singapore, Thailand and Hong Kong (PO)
- 01 Dec 2014 First generic equivalent available in USA for Hypertension